Cyclo Therapeutics, Inc.

CYTH

US23254X2018

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
1.25 ^USD	+2.46%		-1.57%	-21.38%

Jul. 01	Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) added to Russell 3000E Value Index	CI
Jul. 01	Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) added to Russell 3000E Index	CI

George L. Fails Resigns as Director Of CTD Holdings, Inc

April 03, 2017 at 04:02 pm EDT

On March 20, 2017, George L. Fails notified the Board of Directors of CTD Holdings, Inc. of his resignation as a director, effective April 1, 2017.

Latest news about Cyclo Therapeutics, Inc.

Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) added to Russell 3000E Value Index	Jun. 30	CI
Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) added to Russell 3000E Index	Jun. 30	CI
Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) added to Russell Microcap Index	Jun. 30	CI
Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) added to Russell Microcap Growth Index	Jun. 30	CI
Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) added to Russell 3000E Growth Index	Jun. 30	CI
Cyclo Therapeutics, Inc.(NasdaqCM:CYTH) added to Russell Microcap Value Index	Jun. 30	CI
Cyclo Therapeutics, Inc. announced that it has received $2 million in funding from Rafael Holdings, Inc.	Jun. 10	CI
Cyclo Therapeutics, Inc. Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC Trial of Niemann-Pick Type C1	May. 30	CI
Cyclo Therapeutics Files $100 Million Mixed Shelf	May. 24	MT
Cyclo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target	May. 01	MT
Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Cyclo Therapeutics Granted Patent Covering Use of Trappsol Cyclo for Alzheimer's Disease	Mar. 14	MT
Cyclo Therapeutics, Applied Molecular Transport Complete Merger	Dec. 27	MT
Cyclo Therapeutics, Inc. Appoints Shawn Cross to the Board of Directors	Dec. 27	CI
Cyclo Therapeutics, Inc. completed the acquisition of Applied Molecular Transport Inc. from a group of shareholders for $10.2 million.	Dec. 26	CI
Cyclo Therapeutics, Inc. Announces Positive Outcome from Type C Meeting with U.S. FDA Discussing Trappsol Cyclo Clinical Program for Treatment of Niemann-Pick Disease Type C1	Dec. 18	CI
Cyclo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	Nov. 10	MT
Investors Parse Powell Remarks as US Futures Advance Slightly in Friday Trading	Nov. 10	MT
Top Premarket Decliners	Nov. 10	MT
Cyclo Therapeutics, Inc. announced that it has received $2.147009 million in funding	23-10-19	CI
North American Morning Briefing : Rising Oil -2-	23-09-28	DJ
Maxim Upgrades Cyclo Therapeutics to Buy From Hold With $4 Price Target	23-09-27	MT
Cyclo Therapeutics, Applied Molecular Transport Agree to Merge	23-09-21	MT

Chart Cyclo Therapeutics, Inc.

Duration

Period

More charts

Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing transformative therapies for rare and neurological diseases with limited treatment options. The Companyâs Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin. It is an orphan drug designated product in the United States and Europe, and is the subject of four formal clinical trials for Niemann-Pick Disease Type C (NPC) disease. NPC is a rare and fatal autosomal recessive genetic disease resulting in disrupted cholesterol metabolism that impacts the brain, lungs, liver, spleen, and other organs. The Company is also engaged in conducting a Phase 2b clinical trial using Trappsol Cyclo intravenously in early Alzheimerâs disease (NCT05607615) based on encouraging data from an Expanded Access program for Alzheimerâs disease (NCT03624842).

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cyclo Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.25 USD

Average target price

3.2 USD

Spread / Average Target

+156.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CYCLO THERAPEUTICS, INC.	-21.38%	35.77M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals

Cyclo Therapeutics, Inc.

Equities

CYTH

US23254X2018

Pharmaceuticals

George L. Fails Resigns as Director Of CTD Holdings, Inc

Latest news about Cyclo Therapeutics, Inc.

Chart Cyclo Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for Cyclo Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals